Return on Assets (ROA)
since 2005
Calculation
Thermo Fisher Scientific Inc., ROA, long-term trends, calculation
| ROA | = | 100 | × | Net income attributable to Thermo Fisher Scientific Inc.1 | ÷ | Total assets1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 6.51% | = | 100 | × | 6,335) | ÷ | 97,321) |
| Dec 31, 2023 | 6.07% | = | 100 | × | 5,995) | ÷ | 98,726) |
| Dec 31, 2022 | 7.15% | = | 100 | × | 6,950) | ÷ | 97,154) |
| Dec 31, 2021 | 8.12% | = | 100 | × | 7,725) | ÷ | 95,123) |
| Dec 31, 2020 | 9.23% | = | 100 | × | 6,375) | ÷ | 69,052) |
| Dec 31, 2019 | 6.33% | = | 100 | × | 3,696) | ÷ | 58,381) |
| Dec 31, 2018 | 5.22% | = | 100 | × | 2,938) | ÷ | 56,232) |
| Dec 31, 2017 | 3.93% | = | 100 | × | 2,225) | ÷ | 56,669) |
| Dec 31, 2016 | 4.40% | = | 100 | × | 2,022) | ÷ | 45,908) |
| Dec 31, 2015 | 4.83% | = | 100 | × | 1,975) | ÷ | 40,889) |
| Dec 31, 2014 | 4.42% | = | 100 | × | 1,894) | ÷ | 42,852) |
| Dec 31, 2013 | 4.00% | = | 100 | × | 1,273) | ÷ | 31,863) |
| Dec 31, 2012 | 4.29% | = | 100 | × | 1,178) | ÷ | 27,445) |
| Dec 31, 2011 | 4.96% | = | 100 | × | 1,330) | ÷ | 26,834) |
| Dec 31, 2010 | 4.85% | = | 100 | × | 1,036) | ÷ | 21,349) |
| Dec 31, 2009 | 3.93% | = | 100 | × | 850) | ÷ | 21,625) |
| Dec 31, 2008 | 4.71% | = | 100 | × | 994) | ÷ | 21,090) |
| Dec 31, 2007 | 3.59% | = | 100 | × | 761) | ÷ | 21,207) |
| Dec 31, 2006 | 0.79% | = | 100 | × | 169) | ÷ | 21,262) |
| Dec 31, 2005 | 5.25% | = | 100 | × | 223) | ÷ | 4,252) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in millions
The data reflects the financial performance and position of the company over a 20-year period, with key indicators such as net income, total assets, and return on assets (ROA) provided for each year.
- Net Income Trends
- Net income shows a general upward trajectory from 2005 to 2024, with some fluctuations. Starting at $223 million in 2005, it experienced a dip in 2006 to $169 million, followed by a substantial increase reaching $994 million in 2008. After a moderate decline in 2009 (to $850 million), net income resumed growth, peaking strongly in 2020 at $6,375 million and reaching a high of $7,725 million in 2021. Subsequently, net income slightly decreased in the following years, stabilizing around $6,000 to $6,300 million by 2024.
- Total Assets Evolution
- Total assets rose substantially over the period. Beginning at $4,252 million in 2005, the company saw a rapid expansion to over $21 billion by 2006, maintaining a relatively steady level through 2009. Assets again increased sharply from 2012 onwards, reaching $69,052 million in 2020, and further surging to nearly $98,000 million by 2022 and 2023, before a slight reduction to $97,321 million in 2024. This indicates a significant growth in asset base, likely due to acquisitions, investments, or organic growth.
- Return on Assets (ROA) Dynamics
- ROA experienced variability throughout the years, starting at 5.25% in 2005 and dropping notably to 0.79% in 2006, coinciding with a substantial increase in total assets but a decrease in net income. The ratio rebounded in subsequent years, fluctuating mostly between 3.5% and 5%, with a notable recovery and improvement peaking at 9.23% in 2020. Despite high asset growth, ROA remained robust, staying above 6% for the most recent years, indicating an overall effective asset utilization in generating profits.
- Summary of Observations
- The company showed strong net income growth especially in the last decade, paralleling a significant increase in total assets. While the large surge in assets initially pressured ROA, profitability efficiency improved over time, reaching its highest efficiency in 2020. Slight declines in net income and ROA in the last years suggest a potential stabilization or minor contraction phase following expansive growth. Overall, the financial data denotes a resilient and growing company with increasing scale and relatively stable profitability ratios.
Comparison to Competitors
Thermo Fisher Scientific Inc., ROA, long-term trends, comparison to competitors
| Thermo Fisher Scientific Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 6.51% | 3.17% | 4.45% | -9.66% | 5.03% | 13.45% | 0.81% | 7.81% | 14.62% | 3.76% | 11.69% | -2.38% |
| Dec 31, 2023 | 6.07% | 3.61% | 6.91% | 8.43% | 5.64% | 8.19% | 9.12% | 20.98% | 0.34% | 0.94% | 11.95% | 15.92% |
| Dec 31, 2022 | 7.15% | 8.53% | 10.06% | 6.53% | 8.55% | 12.62% | 7.27% | 9.57% | 13.30% | 15.91% | 14.85% | 18.30% |
| Dec 31, 2021 | 8.12% | 7.88% | 9.63% | 6.40% | 7.73% | 11.44% | 9.16% | 11.47% | 12.35% | 12.11% | 31.75% | 17.44% |
| Dec 31, 2020 | 9.23% | 3.07% | 11.54% | -7.61% | 4.79% | 13.28% | 0.18% | 8.41% | 7.72% | 6.23% | 20.47% | 23.07% |
| Dec 31, 2019 | 6.33% | 8.84% | 13.13% | 2.65% | 4.85% | 21.17% | 8.74% | 9.59% | 11.66% | 9.72% | 14.29% | 14.15% |
| Dec 31, 2018 | 5.22% | 9.58% | 12.64% | 14.06% | 5.54% | 7.36% | 8.57% | 10.00% | 7.53% | 7.00% | 20.83% | 33.57% |
| Dec 31, 2017 | 3.93% | 7.50% | 2.48% | 3.00% | 5.34% | -0.45% | 6.58% | 0.83% | 2.72% | 12.40% | 13.67% | 7.43% |
| Dec 31, 2016 | 4.40% | 9.01% | 9.95% | 13.22% | 5.64% | 7.05% | 23.70% | 11.71% | 4.11% | 4.20% | 12.84% | -3.87% |
| Dec 31, 2015 | 4.83% | 9.70% | 9.69% | 4.93% | 6.96% | 6.77% | 34.93% | 11.55% | 4.36% | 4.16% | 11.34% | -22.26% |
| Dec 31, 2014 | 4.42% | 6.44% | 7.47% | 5.94% | 7.02% | 6.43% | 34.91% | 12.45% | 12.12% | 5.40% | 8.99% | -31.63% |
| Dec 31, 2013 | 4.00% | 14.14% | 7.68% | 6.64% | 7.77% | 13.29% | 13.67% | 10.42% | 4.17% | 12.78% | 14.38% | -19.19% |
| Dec 31, 2012 | 4.29% | 19.53% | 8.00% | 5.46% | 7.26% | 11.89% | 12.20% | 8.94% | 5.81% | 7.84% | 36.06% | -3.88% |
| Dec 31, 2011 | 4.96% | — | 7.54% | 11.25% | 7.25% | 12.92% | 16.20% | 8.51% | 5.97% | 5.32% | -16.75% | 1.34% |
| Dec 31, 2010 | 4.85% | — | 10.64% | 9.98% | 8.07% | 16.35% | 25.03% | 12.96% | 0.81% | 4.23% | -9.59% | -43.74% |
| Dec 31, 2009 | 3.93% | — | 11.62% | 34.22% | 5.88% | 15.76% | 27.18% | 12.95% | 11.51% | 4.05% | -9.15% | -32.84% |
| Dec 31, 2008 | 4.71% | — | 11.51% | 17.76% | 7.53% | -7.09% | 28.65% | 15.25% | 16.54% | 7.29% | -12.34% | -46.90% |
| Dec 31, 2007 | 3.59% | — | 9.14% | 8.27% | 7.84% | 11.02% | 27.68% | 13.06% | 6.77% | 7.07% | -11.28% | -65.05% |
| Dec 31, 2006 | 0.79% | — | 8.73% | 6.20% | 8.72% | 12.13% | -29.12% | 15.67% | 9.95% | 16.84% | -17.49% | -22.45% |
| Dec 31, 2005 | 5.25% | — | 12.54% | 10.66% | 9.80% | 8.05% | 21.62% | 17.94% | 10.33% | 6.88% | -22.54% | -37.05% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Thermo Fisher Scientific Inc., ROA, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Thermo Fisher Scientific Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2024 | 6.51% | 5.30% |
| Dec 31, 2023 | 6.07% | 7.25% |
| Dec 31, 2022 | 7.15% | 10.67% |
| Dec 31, 2021 | 8.12% | 10.42% |
| Dec 31, 2020 | 9.23% | 5.45% |
| Dec 31, 2019 | 6.33% | 9.02% |
| Dec 31, 2018 | 5.22% | 8.97% |
| Dec 31, 2017 | 3.93% | 5.28% |
| Dec 31, 2016 | 4.40% | 8.61% |
| Dec 31, 2015 | 4.83% | 8.93% |
| Dec 31, 2014 | 4.42% | 9.45% |
| Dec 31, 2013 | 4.00% | 9.46% |
| Dec 31, 2012 | 4.29% | 8.30% |
| Dec 31, 2011 | 4.96% | 7.30% |
| Dec 31, 2010 | 4.85% | 7.07% |
| Dec 31, 2009 | 3.93% | 10.02% |
| Dec 31, 2008 | 4.71% | 10.37% |
| Dec 31, 2007 | 3.59% | 8.86% |
| Dec 31, 2006 | 0.79% | 11.91% |
| Dec 31, 2005 | 5.25% | 10.42% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Thermo Fisher Scientific Inc., ROA, long-term trends, comparison to industry (health care)
| Thermo Fisher Scientific Inc. | Health Care | |
|---|---|---|
| Dec 31, 2024 | 6.51% | 5.25% |
| Dec 31, 2023 | 6.07% | 6.71% |
| Dec 31, 2022 | 7.15% | 8.71% |
| Dec 31, 2021 | 8.12% | 8.70% |
| Dec 31, 2020 | 9.23% | 5.45% |
| Dec 31, 2019 | 6.33% | 7.57% |
| Dec 31, 2018 | 5.22% | 6.72% |
| Dec 31, 2017 | 3.93% | 5.31% |
| Dec 31, 2016 | 4.40% | 7.18% |
| Dec 31, 2015 | 4.83% | 7.54% |
| Dec 31, 2014 | 4.42% | 8.41% |
| Dec 31, 2013 | 4.00% | 8.58% |
| Dec 31, 2012 | 4.29% | 7.94% |
| Dec 31, 2011 | 4.96% | 7.22% |
| Dec 31, 2010 | 4.85% | 7.11% |
| Dec 31, 2009 | 3.93% | 9.45% |
| Dec 31, 2008 | 4.71% | 9.08% |
| Dec 31, 2007 | 3.59% | 8.51% |
| Dec 31, 2006 | 0.79% | 10.37% |
| Dec 31, 2005 | 5.25% | 9.62% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).